Genfit S.A.
GNFT
Rank in Stocks
#10998
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its... Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
Share Price
$12.37
Last synced: 2026-11-09
Market Cap
$618.80M
Change (1 day)
4.66%
Change (1 year)
190.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Genfit S.A. (GNFT)
Category
Healthcare
Operating Margin for Genfit S.A. (GNFT)
Operating Margin as of November 2026 TTM: -130.38%
According to Genfit S.A.'s latest financial reports, its current operating margin (TTM) is -130.38%. At the end of 2025 the company had an operating margin of -90.05%.
Operating Margin history for Genfit S.A. from 2004 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -130.38% | 44.79% |
| 2025 | -90.05% | -1,937.76% |
| 2024 | 4.90% | -105.27% |
| 2023 | -93.05% | -31.79% |
| 2022 | -136.41% | -443.26% |
| 2021 | 39.74% | -100.37% |
| 2020 | -10,836.21% | 5,678.39% |
| 2019 | -187.53% | -99.81% |
| 2018 | -100,701.45% | 109.59% |
| 2017 | -48,046.61% | 299.47% |
| 2016 | -12,027.46% | 258.59% |
| 2015 | -3,354.08% | 213.75% |
| 2014 | -1,069.04% | 93.12% |
| 2013 | -553.56% | 19.98% |
| 2012 | -461.39% | 40.53% |
| 2011 | -328.32% | 61.08% |
| 2010 | -203.82% | 82.96% |
| 2009 | -111.40% | 88.62% |
| 2008 | -59.06% | -6.57% |
| 2007 | -63.21% | 1,049.27% |
| 2006 | -5.50% | -141.92% |
| 2005 | 13.12% | -39.46% |
| 2004 | 21.67% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.30% |
US
|
|
| -149.01% | -98.86% |
US
|
|
| 25.57% | -100.20% |
AU
|
|
| 31.23% | -100.24% |
BE
|
|
| 29.35% | -100.23% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Genfit S.A.'s operating margin
What is Genfit S.A.'s operating margin?
Genfit S.A.'s operating margin is -130.38%, as of Nov 2026.
What was Genfit S.A.'s operating margin in 2025?
In 2025, Genfit S.A.'s operating margin was -90.05%, compared with 4.90% in 2024.
How has Genfit S.A.'s operating margin changed since 2020?
From 2020 to 2025, Genfit S.A.'s operating margin was highest in 2021 (39.74%) and lowest in 2020 (-10,836.21%).
How does Genfit S.A.'s operating margin compare with similar companies?
Genfit S.A.'s operating margin (-130.38%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.